FLC Capital Advisors Makes New $279,000 Investment in GSK plc (NYSE:GSK)

FLC Capital Advisors bought a new position in GSK plc (NYSE:GSK) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 8,238 shares of the pharmaceutical company’s stock, valued at approximately $279,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. FMR LLC lifted its stake in GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after acquiring an additional 2,224,345 shares during the period. Fisher Asset Management LLC increased its position in GSK by 4.9% during the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after purchasing an additional 870,449 shares during the period. Primecap Management Co. CA raised its holdings in shares of GSK by 2.4% in the 3rd quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock valued at $607,222,000 after purchasing an additional 342,365 shares in the last quarter. Provident Trust Co. lifted its position in shares of GSK by 1.7% in the 3rd quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock worth $161,623,000 after purchasing an additional 66,765 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC boosted its stake in shares of GSK by 30.8% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after purchasing an additional 833,080 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 13th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Seven equities research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, GSK has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Stock Up 0.0 %

Shares of GSK stock opened at $33.46 on Monday. The stock’s fifty day moving average price is $34.02 and its 200 day moving average price is $37.98. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.92. The company has a market cap of $69.34 billion, a price-to-earnings ratio of 21.72, a price-to-earnings-growth ratio of 1.44 and a beta of 0.63.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were issued a dividend of $0.3928 per share. The ex-dividend date was Friday, November 15th. This represents a $1.57 annualized dividend and a dividend yield of 4.70%. This is an increase from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio is 96.10%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.